Breast cancer: Genetic predisposition and exposure to radiation

Molecular Carcinogenesis

Volumn 26, Issue 3, 1999, Pages 143-149

  Bennett, L Michelle ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

(Genetic) susceptibility; BRCA1; BRCA2; Breast cancer; Radiation

Indexed keywords

BRCA1 PROTEIN; PROTEIN P53;

ATAXIA TELANGIECTASIA; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; DNA DAMAGE; FAMILY HISTORY; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW;

ANIMALS; BREAST NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASMS, RADIATION-INDUCED;

ATAXIA; ATAXIA TELANGIECTASIA;

EID: 0032753201     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199911)26:3<143::AID-MC2>3.0.CO;2-S     Document Type: Review

References (68)

1. Goss PE, Sierra S. Current perspectives on radiation-induced breast cancer. J Clin Oncol 1998;16:338-347.
2. Crompton NEA. Programmed cellular response in radiation oncology. Acta Oncol 1998;37 (Suppl 11): 1-49.
3. Lane D. Awakening angels. Nature 1998;394:616-617.
4. Storer JB. Acute responses to ionizing radiation. In: Earl L. Green, editor. Biology of the laboratory mouse. New York: Dover; 1972. p 427.
5. Hutchinson F. Molecular biology of mutagenesis of mammalian cells by ionizing radiation. Semin Cancer Biol 1998;4:85-92.
6. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
7. Barcellos-Hoff MH. The potential influence of radiation-induced microenvironments in neoplastic progression. Journal of Mammary Gland Biology and Neoplasia 1998;3:165-175.
8. Howe GR, McLaughlin J. Breast cancer mortality between 1950 and 1987 after exposure to fractionated moderate-dose-rate ionizing radiation in the Canadian Fluoroscopy Cohort Study and a comparison with breast cancer mortality in the Atomic Bomb Survivors Study. Radiat Res 1996; 145:694-707.
9. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62:676-689.
10. Rahman N, Stratton M. The genetics of breast cancer susceptibility. Annu Rev Genet 1998;32:95-121.
11. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997;88: 265-275.
12. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997;386:804-810.
13. Chen P-L, Chen C-F, Chen Y, Xiao J, Sharp ZD, Lee W-H. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci USA 1998;95:5287-5292.
14. Patel KJ, Yu VPC, Lee HS, et al. Involvement of Brca2 in DNA repair. Molecular Cell 1998;1:347-357.
15. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998;281:1009-1012.
16. Chen J-J, Sliver D, Cantor S, Livingston DM, Scully R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res 1999;59: 1752s-1756s.
17. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997;26: 997-1003.
18. Mettler FA, Upton AC, Kelsey CA, Ashby RN, Rosenberg RD, Linver MN. Benefits versus risks from mammography. Cancer 1996;77:903-909.
19. Suleiman OH, Spelic DC, McCrohan JL, Symonds GR, Houn F. Mammography in the 1990's: The United States and Canada. Radiology 1999;210:345-351.
20. Taubes G. The breast screening brawl. Science 1997;275: 1056-1059.
21. Fletcher SW. Whither scientific deliberation in health policy recommendations? N Engl J Med 1997;336: 1180-1183.
22. Chakraborty R, Sankaranarayanan K. Mutations in the BRCA1 gene: Implications of inter-population differences for predicting the risk of radiation-induced breast cancers. Genet Res 1998;72:191-198.
23. Bertwistle D, Ashworth A. Functions of the BRCA1 and BRCA2 genes. Curr Opin Genet Dev 1998;8:14-20.
24. Briggs PJ, Bradley A. A step toward genotype-based therapeutic regimens for breast cancer in patients with BRCA2 mutations? J Natl Cancer Inst 1998;90:951-953.
25. Harris JR, Recht A. Conservative surgery and radiotherapy. In: Harris JA, editor. Breast diseases. Philadelphia: Lippincott, 1991. p 388-419.
26. Boice JD, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 1992;326:781-785.
27. Frass BA, Robertson PL, Lichter AS. Dose to the contralateral breast due to primary breast irradiation. Int J Radiat Oncol Biol Phys 1985;11:485-497.
28. Hass JA, Schultz DJ, Peterson ME, Solin LJ. An analysis of age and family history on outcome after breast-conservation treatment: The University of Pennsylvania experience. Cancer J Sci Am 1998;4:308-315.
29. Harrold EV, Turner BC, Matloff ET, et al. Local recurrence in the conservatively treated breast cancer patient: A correlation with age and family history. Cancer J Sci Am 1998;4:302-307.
30. Robson M, Gilewski T, Haas B, et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998;16:1642-1649.
31. Verhoog LC, Brekelmans CTM, Seynaeve C, et al. Survival and tumor characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351:316-321.
32. Gaffney DK, Brohet RM, Lewis CM, et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 1998; 47:129-136.
33. Cressman VL, Backlulnd DC, Hicks EM, Gowen LC, Godfrey V, Koller BH. Mammary tumor formation in p53- and BRCA1-deficient mice. Cell Growth Differ 1999;10:1-10.
34. Lossie AC, MacPhee M, Burchberg AM, Camper SA. Mouse chromosome 11. Mamm Genome 1994;5:S164-S180.
35. Bennett LM, Haugen-Strano A, Cochran C, Brownlee HA, Fiedorek FT Jr, Wiseman RW. Isolation of the mouse homologue of BRCA1 and genetic mapping to mouse chromosome 11. Genomics 1995;29:576-581.
36. Hakem R, de la Pompa JL, Mak TW. Developmental studies of Brca1 and Brca2 knock-out mice. Journal of Mammary Gland Biology and Neoplasia 1998;3:431-445.
37. Xu X, Wagner K-U, Larson D, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumor formation. Nat Genet 1999; 22:37-43.
38. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to Pl-3 kinase. Science 1995;268:1749-1753.
39. Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996;92: 130-134.
40. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987;316:1289-1294.
41. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991;325:1831-1836.
42. Easton DF. Cancer risks in A-T heterozygotes. Int J Radiat Biol 1994;66:S177-S182.
43. Bishop DT, Hopper J. AT-tributable risks? Nat Genet 1997; 15:226.
44. FitzGerald M, Bean J, Hegde S, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 1997;15:307-310.
45. Chen J, Birkholtz G, Lindblom P, Rubio C, Lindblom A. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res 1998;58:1376-1379.
46. Bebb G, Glickman B, Gelmon K, Gatti R. "AT risk" for breast cancer. Lancet 1997:349:1784-1785.
47. Werneke U. Ataxia telangiectasia and risk of breast cancer. Lancet 1997;350:739-740.
48. Ramsay J, Birrell G, Lavin M. Testing for mutations of the ataxia telangiectasia gene in radiosensitive breast cancer patients. Radiother Oncol 1998;47:125-128.
49. Larson GP, Ahang G, Ding S, et al. An allelic variant at the ATM locus is implicated in breast cancer susceptibility. Genetic Testing 1997/98:1:165-170.
50. Barlow C, Hirotsune S, Paylor R, et al. Atm-deficient mice: A paradigm of ataxia telangiectasia. Cell 1996;86:159-171.
51. Westphal C, Rowan S, Schmaltz C, Elson A, Fisher D, Leder P. Atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nat Genet 1997;16:397-401.
52. Herzog K-H, Chong MJ, Kapsetaki M, Morgan JI, McKinnon PJ. Requirement of Atm in ionizing radiation-induced cell death in the developing central nervous system. Science 1998;280:1089-1091.
53. Westphal C, Hoyes KP, Canman CE, et al. Loss of atm radiosensitizes multiple p53 null tissues. Cancer Res 1998; 58:5637-5639.
54. Barlow C, Eckhaus MA, Schaffer AA, Wynshaw-Boris A. Atm haploinsufficiency results in increased sensitivity to sublethal does of ionizing radiation in mice. Nat Genet 1999;21:359-360.
55. Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutations of chromosome 5q21 genes in FAP and colorectal-cancer patients. Science 1991;253:665-669.
56. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis-coli gene. Cell 1991;66:589-600.
57. Woodage T, King SM, Wacholder S, et al. The APC 11307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet 1998;20:62-65.
58. Redston M, Nathanson KL, Yuan ZQ, et al. The APC I1307K allele and breast cancer risk. Nat Genet 1998;20: 13-14.
59. Fodde R, Edelmann W, Yang K, et al. A targeted chain-termination mutation in the mouse APC gene results in multiple intestinal tumors. Proc Natl Acad Sci USA 1994;91:8969-8973.
60. Su L-K, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256:668-670.
61. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-324.
62. Min, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. Proc Natl Acad Sci USA 1993;90: 8977-8981.
63. van der Houven van Oordt CW, Smits R, Williamson SLH, et al. Intestinal and extra-intestinal tumor multiplicities in the Apc1638N mouse model after exposure to x-rays. Carcinogenesis 1997;18:2197-2203.
64. Ullrich RL, Jernigan MC, Satterfield LC, Bowles ND. Radiation carcinogenesis: Time-dose relationships. Radiat Res 1987;111:179-184.
65. Ullrich RL, Bowles ND, Satterfield LC, Davis CM. Strain-dependent susceptibility to radiation-induced mammary cancer is a result of differences in epithelial cell sensitivity to transformation. Radiat Res 1996;146:353-355.
66. DeOme KB, Faulkin LJ Jr, Bern HA, Blair PB. Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free mammary fat pads of female C3H mice. Cancer Res 1959;19:515-520.
67. Ponnaiya B, Cornforth MN, Ullrich RL. Radiation-induced chromosomal instability in BALB/c and C57BL/6 mice: The difference is as clear as black and white. Radiat Res 1997;147:121-125.
68. Hasten CK, Travis EL. Murine susceptibility to radiation-induced pulmonary fibrosis is influenced by a genetic factor implicated in susceptibility to bleomycin-induced pulmonary fibrosis. Cancer Res 1997;57:5286-5291.